Anupam Rasayan India Limited (ANURAS) — Board Meeting | 23 May 2026(3 announcements)

Anupam Rasayan India Limited announced on May 23, 2026 that its board approved the acquisition of up to 74.20% of Bliss GVS Pharma Limited through a share purchase agreement, including up to 43.30% via direct purchase at Rs. 299 per share costing up to Rs. 1369.51 crores, plus an open offer for 26% at the same price. The deal includes options to acquire residual shares later and aims to strengthen its pharmaceutical value chain position.

Anupam Rasayan India Limited announced on May 23, 2026 that its board approved the acquisition of up to 74.20% of Bliss GVS Pharma Limited through a share purchase agreement, including up to 43.30% via direct purchase at Rs. 299 per share costing up to Rs. 1369.51 crores, plus an open offer for 26% at the same price. The deal includes options to acquire residual shares later and aims to strengthen its pharmaceutical manufacturing platform and unlock synergies.

Anupam Rasayan India Limited announced the re-appointment of K.B. Daliya & Associates as internal auditor and Bhanwarlal Gurjar & Co. as cost auditor for the financial year 2026-27 during its board meeting on May 23, 2026, as disclosed under SEBI Regulation 30. The appointments were approved based on the Audit Committee's recommendation and are part of routine compliance requirements for ongoing financial oversight. The firm profiles highlight their extensive experience in audit and consultancy services relevant to the company's operations in chemicals and pharmaceuticals.